nCipher: New Digital Initiatives, IoT and Cloud Adoption Driving the Use of Trusted Cryptography Revealed by 2019 Global Encryption Trends Study
nCipher Security, the provider of trust, integrity and control for business critical information and applications, announces that as organizations embrace the cloud and new digital initiatives such as the internet of things (IoT), blockchain and digital payments the use of trusted cryptography to protect their applications and sensitive information is at an all-time high, according to the 2019 Global Encryption Trends Study from the Ponemon Institute.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190328005199/en/
nCipher Security 2019 Ponemon Global Encryption Trends Report (Graphic: Business Wire)
With corporate data breaches making the headlines on an almost daily basis, the deployment of an overall encryption strategy by organizations around the world has steadily increased. This year, 45% of respondents say their organization has an overall encryption plan applied consistently across the entire enterprise with a further 42% having a limited encryption plan or strategy that is applied to certain applications and data types.
Threats, drivers and priorities
Employee mistakes continue to be the most significant threat to sensitive data (54%), more than external hackers (30%) and malicious insiders (21%) combined. In contrast, the least significant threats to the exposure of sensitive or confidential data include government eavesdropping (12%) and lawful data requests (11%).
The main driver for encryption is protection of an enterprise’s intellectual property and the personal information of customers – both 54% of respondents.
With more data to encrypt and close to 2/3 of respondents deploying 6 or more separate products to encrypt it, policy enforcement (73%) was selected as the most important feature for encryption solutions. In previous years, performance consistently ranked as the most important feature.
Cloud data protection requirements continue to drive encryption use, with encryption across both public and private cloud use cases growing over 2018 levels, and organizations prioritizing solutions that operate across both enterprise and cloud environments (68%).
Data discovery the number one challenge
With the explosion and proliferation of data that comes from digital initiatives, cloud use, mobility and IoT devices, data discovery continues to be the biggest challenge in planning and executing a data encryption strategy with 69% of respondents citing this as their number one challenge.
Trust, integrity, control
The use of hardware security modules (HSMs) grew at a record year-over-year level from 41% in 2018 to 47%, indicating a requirement for a hardened, tamper-resistant environment with higher levels of trust, integrity and control for both data and applications. HSM usage is no longer limited to traditional use cases such as public key infrastructure (PKI), databases, application and network encryption (TLS/SSL); the demand for trusted encryption for new digital initiatives has driven significant HSM growth over 2018 for code signing (up 13%), big data encryption (up 12%), IoT root of trust (up 10%) and document signing (up 8%). Additionally, 53% of respondents report using on-premises HSMs to secure access to public cloud applications.
Dr. Larry Ponemon, chairman and founder of the Ponemon Institute,
“The use of encryption is at an all-time high, driven by the need to address compliance requirements such as the EU General Data Protection Regulation (GDPR), California Data Breach Notification Law and Australia Privacy Amendment Act 2017, and the need to protect sensitive information from both internal and external threats as well as accidental disclosure. Encryption usage is a clear indicator of a strong security posture with organizations that deploy encryption being more aware of threats to sensitive and confidential information and making a greater investment in IT security.”
John Grimm, senior director of strategy and business development at
nCipher Security, says:
“Organizations are under relentless pressure to protect their business critical information and applications and meet regulatory compliance, but the proliferation of data, concerns around data discovery and policy enforcement, together with lack of cybersecurity skills makes this a challenging environment. nCipher empowers customers by providing a high assurance security foundation that ensures the integrity and trustworthiness of their data, applications and intellectual property.”
Other key trends include:
- The highest prevalence of an enterprise encryption strategy is reported in Germany (67%) followed by the United States (65%), Australia (51%), and the United Kingdom (50%).
- Payment-related data (55% of respondents) and financial records (54% of respondents) are most likely to be encrypted. Financial records had the largest increase on this list over last year, up 4%.
- The least likely data type to be encrypted is health-related information (24% of respondents), which is a surprising result given the sensitivity of health information and the recent high-profile healthcare data breaches.
- 61% of respondents classify key management as having a high level of associated “pain” (a rating of 7+ on a scale of 10). This figure is almost identical to the 63% of organizations that use six or more separate encryption products, suggesting there is clear correlation between the two findings.
- Support for both cloud and on-premises deployment of encryption has risen in importance as organizations have increasingly embraced cloud computing and look for consistency across computing styles.
Download the 2019 Global Encryption Trends Study here.
2019 Global Encryption Trends Study methodology
The 2019 Global Encryption Trends Study, based on research by the Ponemon Institute, captures how organizations around the world are dealing with compliance, increased threats, and the implementation of encryption to protect their business critical information and applications. 5,856 individuals were surveyed across multiple industry sectors in 14 countries/regions: Australia, Brazil, France, Germany, India, Japan, Mexico, the Middle East (which is a combination of respondents located in Saudi Arabia and the United Arab Emirates), the Russian Federation, South Korea, the United Kingdom, the United States and, two new regions in Asia for the first time, Southeast Asia (Indonesia, Malaysia, Philippines, Thailand, and Vietnam) and Hong Kong and Taiwan.
About nCipher Security
Today’s fast moving digital environment enhances customer satisfaction, gives competitive advantage and improves operational efficiency. It also multiplies the security risks. nCipher Security, a leader in the general purpose hardware security module (HSM) market, empowers world-leading organizations by delivering trust, integrity and control to their business critical information and applications.
Our cryptographic solutions secure emerging technologies – cloud, IoT, blockchain, digital payments – and help meet new compliance mandates, using the same proven technology that global organizations depend on today to protect against threats to their sensitive data, network communications and enterprise infrastructure. We deliver trust for your business critical applications, ensuring the integrity of your data and putting you in complete control – today, tomorrow, at all times. www.ncipher.com
Bospar PR PRfornCipher@bospar.com
Hotwire PR nCipher@hotwireglobal.com
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AqVida and Phyton Biotech Receive Approval from European Directorate of Quality Medicines for AqVida’s Cancer-fighting Paclitaxel Injectable Finished Dosage Formulation18.4.2019 10:00:00 CEST | Pressemelding
Phyton Biotech, a German/North American Plant Cell Fermentation (PCF®) technology company, and AqVida, a German oncology Finished Dosage Formulation (FDF) manufacturer, are pleased to announce today that they have received European approval from the EDQM (European Directorate of Quality Medicines) for AqVida’s paclitaxel injectable FDF. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005161/en/ Phyton Biotech is the world’s leading manufacturer of paclitaxel active pharmaceutical ingredient (API), utilizing its prorprietary PCF® technology process. Under the strategic partnership with AqVida, Phyton Biotech will be the exclusive supplier of paclitaxel API for AqVida’s Taxol generic formulation, which is produced in AqVida’s new state-of-the-art injectable manufacturing facility located in Dassow, Germany. AqVida’s ultramodern robotic manufacturing line, designed for filling cytotoxic injectables, will be utilized to pro
Racketeering Lawsuit Filed by Boies Schiller Flexner LLP Alleges Czech Oligarch Defrauds US Hedge Fund and Former Partner Out of Over $1 Billion18.4.2019 07:41:00 CEST | Pressemelding
New York hedge fund, Kingstown Capital Management L.P, and other plaintiffs filed a lawsuit on 10 April 2019 in the Southern District of New York against Radovan Vitek, a Czech real estate mogul with business interests throughout Europe, whose fortune Forbes magazine estimates at $3.5 billion. Represented by litigation powerhouse Boies Schiller Flexner LLP, the hedge fund Kingstown Capital Management L.P and Czech investment firm Investhold Ltd allege that Vitek ran an elaborate criminal enterprise that defrauded the plaintiffs out of more than US $1 billion. According to the complaint, Berlin’s largest commercial real estate landlord, Vitek engaged in racketeering activity including wire fraud, mail fraud, money laundering, and other crimes and amassed his wealth at the expense of the plaintiffs, according to the complaint. His commercial interests span multiple jurisdictions including the Czech Republic, Switzerland, Luxembourg, Germany, Croatia and UK. The complaint alleges that Vit
MHI Thermal Systems Develops Demonstration Unit of the World’s First Small-Capacity Residential Air-Conditioner Adopting the Low-GWP R454C Refrigerant18.4.2019 07:21:00 CEST | Pressemelding
Premiering for the first time in the world, Mitsubishi Heavy Industries Thermal Systems, Ltd., a Group company of Mitsubishi Heavy Industries, Ltd. (MHI) (TOKYO: 7011), is adopting R454C, a refrigerant with an extremely low global warming potential (GWP), in a 1-horsepower (HP) class residential air-conditioner. The conventional shortcomings of the R454C,for example; inferior heat exchanger performance attributable to it being a mixed refrigerant have been overcome through the use of proprietary technology that optimize the heat exchanger’s flow volume and other measures. The company has already developed a demonstration unit of the residential air-conditioner featuring R454C and preparations are underway towards mass production with an eye on an initial launch into the European market, where environmental regulations are particularly stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005241/en/ Residential type
Hologic Receives European CE Mark for ThinPrep® Genesis Processor, an Automated Cytology Slide and Molecular Sample System18.4.2019 07:00:00 CEST | Pressemelding
Hologic, Inc. (Nasdaq: HOLX) announced today that the ThinPrep® Genesis processor for cytology slide and molecular test preparation has received a CE IVD mark in Europe. The system features increased automation capabilities, together with ergonomic and chain of custody benefits, compared to older instruments. Most importantly, the instrument will prepare slides for cytology as well as aliquot samples for molecular testing, reducing manual sample handling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005130/en/ ThinPrep Genesis processor (Photo: Business Wire) The Genesis processor is the latest extension of the ThinPrep portfolio, which revolutionized and increased the accuracy of cervical cancer screening with the first liquid-based Pap test in 1996. Hologic launched an updated ThinPrep® 2000 processor in 2017 and received FDA approval in 2018 for the ThinPrep® Integrated Imager, which guides cytotechnologists to ar
Ipsen Completes Acquisition of Clementia Pharmaceuticals18.4.2019 05:00:00 CEST | Pressemelding
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and Clementia Pharmaceuticals (NASDAQ: CMTA) today announced the closing of Ipsen’s acquisition of Clementia following approval of the arrangement by Clementia shareholders and the Quebec Superior Court. Pursuant to the arrangement, Clementia shareholders will receive US$25.00 per share in cash upfront and one contingent value right (CVR) per share entitling them to receive US$6.00 per CVR upon the U.S. Food and Drug Administration's (FDA) acceptance of the regulatory filing for palovarotene for the treatment of multiple osteochondromas (MO). Clementia’s key late-stage clinical asset palovarotene is an investigational retinoic acid receptor gamma (RARγ) selective agonist, for the treatment of two rare bone disorders, fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), and other diseases. The palovarotene regulatory submission for the prevention of heterotopic ossification (HO) in patients with FOP in the U.S.
Sartorius Starts off Fiscal 2019 with a Strong First Quarter18.4.2019 05:00:00 CEST | Pressemelding
Sartorius, a leading international partner of biopharmaceutical research and the industry, started off fiscal 2019 with substantial double-digit growth in order intake, sales revenue and earnings. Consolidated first-quarter sales revenue rose in constant currencies by 16.8% to 435.7 million (reported: +19.4%); order intake increased 16.6% to 482.8 million euros (reported: +19.3%). Sartorius’ underlying EBITDA1) surged 28.7% to 114.0 million euros. Its respective underlying EBITDA margin for the first three months of 2019 was 26.2% (Q1 2018: 24.3%), with a good half a percentage point of this increase resulting from the change in accounting rules2), as expected. Relevant net profit3) for the Group climbed 30.8% to 48.6 million euros. Earnings per ordinary share were 0.71 euros (Q1 2018: 0.54 euros); earnings per preference share, 0.72 euros (Q1 2018: 0.55 euros). “We are very pleased with our first-quarter results,” said Dr. Joachim Kreuzburg, CEO and Executive Board Chairman. “In Biopr